Teva Pharmaceuticals and Direct Relief launched a nationwide program in 2009 to assist people with asthma who did not have insurance. At the end of 2008, the FDA and EPA banned the use of chlorofluorocarbon (CFC) inhalers, which required the transition to environmentally friendly hydrofluoroalkane (HFA) inhalers. This ban resulted in a financial strain on safety net providers, given that the price of a HFA inhaler is more than triple that of a CFC inhaler. Without a generic HFA inhaler on the market, uninsured people with asthma – some 2.5 million Americans – had an even harder time accessing HFA inhalers. For those with asthma, this could result in a number of serious, sometimes life-threatening complications. To address this, Teva donated 500,000 ProAir® HFA inhalers to Direct Relief for distribution among our clinic partners throughout the U.S.